Lonza GroupXSWX:LONN +2.56%82 PB Ratio is 4.66 as of Jun. 25, 2026, which is 11% above its 10-year median of 4.20. GuruFocus rates XSWX:LONN with a GF Score™ of 82/100 and a GF Value™ of CHF592.67 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Lonza Group ranks worse than 79.59% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Lonza Group's share price is CHF528.40. Lonza Group's Book Value per Share for the quarter that ended in Dec. 2025 was CHF113.30. Hence, Lonza Group's PB Ratio of today is 4.66.
The historical rank and industry rank for Lonza Group's PB Ratio or its related term are showing as below:
XSWX:LONN'
s PB Ratio Range Over the Past 10 Years
Min: 2.21 Med: 4.2 Max: 8.48
Current: 4.66
During the past 13 years, Lonza Group's highest PB Ratio was 8.48. The lowest was 2.21. And the median was 4.20.
XSWX:LONN's PB Ratio is ranked worse than 79.59% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs XSWX:LONN: 4.66
During the past 12 months, Lonza Group's average Book Value Per Share Growth Rate was -14.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -7.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 12.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Lonza Group was 30.30% per year. The lowest was -7.40% per year. And the median was 8.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Lonza Group PB Ratio Related Terms
Lonza Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Lonza Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Lonza Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lonza Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Lonza Group's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lonza Group (XSWX:LONN) has a PB Ratio of 4.66 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lonza Group and its competitors. This is 11% above median its historical median of 4.20. Over the past decade, Lonza Group's PB Ratio has ranged from 2.21 to 8.48. According to the industry distribution chart, Lonza Group ranks #156 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 79.6%.
Is Lonza Group's PB Ratio too high?
Lonza Group's current PB Ratio of 4.66 is 11% above median its 10-year median of 4.20. Over the past 10 years, this metric has ranged from a low of 2.21 to a high of 8.48. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Lonza Group's value of 4.66 is 127.3% above this industry median. Based on the distribution chart, Lonza Group ranks #156 out of 196 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Lonza Group has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #156 out of 196 companies for PB Ratio. This places Lonza Group in the lower half of its industry. The industry median PB Ratio is 2.05. Lonza Group's value of 4.66 is 127.3% above this benchmark. Historically, Lonza Group's own PB Ratio has ranged from 2.21 to 8.48 over the past decade. While the company's 10-year median is 4.20 vs. the industry median of 2.05, Lonza Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lonza Group's current PB Ratio of 4.66 is 127.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lonza Group and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lonza Group's current PB Ratio is 4.66, which is 11% above median its own 10-year median of 4.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (XSWX:LONN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF592.67, compared to a current price of CHF528.40 — trading 10.8% below its estimated fair value. The current PB Ratio is 4.66, which is 11% above median its 10-year median of 4.20 and 127.3% above the Medical Diagnostics & Research industry median of 2.05. Lonza Group's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lonza Group (XSWX:LONN), the current PB Ratio is 4.66 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (XSWX:LONN) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued.
The current stock price of CHF528.40 is trading 10.8% below its estimated GF Value™ of CHF592.67.
GuruFocus considers Lonza Group to be Modestly Undervalued.
Key valuation signals for XSWX:LONN:
PB Ratio: 4.66 (11% above median its 10-year median of 4.20)
GF Value™: CHF592.67 vs. price of CHF528.40 (10.8% below fair value)
Industry Position: 127.3% above the Medical Diagnostics & Research median (#156 of 196)
No single metric tells the full story. See the XSWX:LONN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
82GF Score
Get the complete analysis for XSWX:LONN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LONN has been successfully added to your 
